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North American Menopause Society (NAMS), the leading nonprofit scientific organization dedicated to 
improving women’s health and quality of life through an understanding of menopause and healthy aging. Each 
review has commentary from a recognized expert that addresses its clinical relevance. Oversight for this 
e-newsletter was by Nicole Jaff, NCMP, Chair-elect of the 2016 NAMS Education Committee. Opinions 
expressed in the commentaries are those of the authors and are not necessarily endorsed by NAMS or by 
Dr. Jaff.  
 
 
New American Cancer Society 
breast cancer screening guidelines 
continue confusion, controversy 
for women and their providers 
 
Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer 
screening for women at average risk: 2015 guideline update 
from the American Cancer Society. JAMA. 2015;314(15): 
1599-1614. 
 
Summary. The American Cancer Society 
(ACS) has updated its 2003 guidelines for 
screening mammography. The new evidence-
based guidelines focus on women at average 
risk for breast cancer.  
 
Average risk for breast cancer means 
 No personal history of breast cancer 
 No confirmed or suspected genetic 
mutation known to increase risk of breast 
cancer (eg, BRCA) 
 No history of radiotherapy to the chest at a 
young age 
 No significant family history of breast cancer 
 No prior diagnosis of benign proliferative 
breast disease 
 No significant mammographic breast 
density 
The new guidelines are graded according to the 
strength of the recommendation as being either 
“strong” or “qualified.” The ACS defines a 
strong recommendation as one that most women 
should follow. A qualified recommendation 
indicates that clinicians should acknowledge 
that there may be different choices for different 
women and that they must help each woman 
arrive at a management decision based on her 
values and preferences. 
 
The new recommendations are 
 Regular screening mammography starting 
at age 45 years (strong recommendation) 
 Annual screening in women aged 45 to 54 
years (qualified recommendation) 
 Biennial screening beginning at age 55, 
unless the woman prefers to continue annual 
screening (qualified recommendation) 
 Women who desire to initiate annual 
screening between the ages of 40 and 44 
years should be accommodated (qualified 
recommendation) 
 Screening mammography should continue 
as long as a woman is in good health and 
has a life expectancy of at least 10 years 
(qualified recommendation) 
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 Clinical breast examination is not 
recommended at any age (qualified 
recommendation) 
Shortly after the ACS revised guidelines were 
released, the American Congress of 
Obstetricians and Gynecologists (ACOG) issued 
a statement in response, reaffirming their 
current clinical guidelines, saying, “ACOG 
strongly supports shared decision making 
between doctor and patient, and in the case of 
screening for breast cancer, it is essential. We 
recognize that guidelines and recommendations 
evolve as new evidence emerges, but currently 
ACOG continues to support routine 
mammograms beginning at 40 years as well as 
continued use of clinical breast examinations.” 
ACOG’s current recommendations are 
 Screening mammography every year 
for women aged 40 to 49 years 
 Screening mammography every year 
for women aged 50 years or older 
 Breast self-awareness has the potential to 
detect palpable breast cancer and can be 
recommended 
 Clinical breast examination every year 
for women aged 19 years or older 
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hat are the controversies surrounding 
screening for breast cancer? 
 
The primary controversies are the recom-
mendations against routine screening in women 
aged 40 to 44 years, of biennial (rather than 
annual) screening beginning at 55 years, and 
against women performing breast self-
examination. 
Those in favor of the new ACS screening 
guidelines are concerned about lifetime 
radiation exposure and the costs, in terms of 
money, time, and mental well-being, of 
callbacks or false-positive biopsies. 
 
Reasons against continuing annual 
mammography include psychological harms 
(anxiety) to the woman, excess or unnecessary 
imaging tests, unnecessary biopsies in women 
who don’t turn out to have cancer, and 
inconvenience and fear when false-positive 
screening results occur. 
 
Concern is raised regarding overdiagnosis of a 
breast cancer that might never become clinically 
apparent during a woman’s lifetime and 
unnecessary treatments of early, nonaggressive 
breast cancer that may become clinically 
apparent but would not actually shorten a 
woman’s life. 
 
The differences are based on interpretations of 
the benefits and harms of screening. Regular 
mammogram screening finds breast cancer 
earlier when it is easier to treat, has less effect 
on women’s quality of life, and reduces breast 
cancer deaths. 
 
On the other side, an abnormal finding that 
requires further testing to investigate but has no 
effect on prolonging life or decreasing mortality 
leads to unnecessary risks of further tests or 
treatments. 
 
In order to facilitate discussions about the new 
mammographic recommendations with patients, 
we turned to one of our nationally recognized 
breast-imaging specialists, Dr. Jennifer Harvey. 
 
Dr. Harvey discusses her recommendations for 
women at average and high risk for breast 
cancer, including why she continues to 
recommend screening beginning at age 40 and 
continuing annually and her suggestions of 3D-
tomosynthesis or other imaging modalities for 
those with dense breasts or at higher risk.  
 
W 
JoAnn V. Pinkerton, MD, NCMP 
NAMS Executive Director 
Professor of Obstetrics 
and Gynecology 
Division Director of Midlife Health 
University of Virginia 
Charlottesville, Virginia 
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creening mammography saves lives, and 
women should continue to have this 
important test. Breast cancer mortality 
reductions of up to 48% have been 
demonstrated for women aged 40 to 79 years 
who undergo regular screening exams.
1
 The 
debate is really about the age at which to initiate 
screening and the screening interval. The 
greatest benefit from mammography will be 
obtained from annual screening beginning at age 
40 years.  
 
Initiation of screening. Breast cancer 
diagnosed in young women represents a 
disproportionate percentage of breast cancer 
deaths,
2
 likely because of the greater incidence 
of high-grade cancers. Faster tumor doubling 
times observed in younger women require more 
frequent screening intervals to affect mortality, 
and therefore, women aged younger than 
55 years should obtain a mammogram every 
year. 
 
Early initiation of screening increases the 
likelihood of a false-positive mammogram, 
which may lead to anxiety. For the vast majority 
of women, this represents a minimal and 
temporary state of anxiety until additional 
images are obtained that resolve the questioned 
screening finding. Certainly, some women will 
experience a much higher level of anxiety 
related to false-positive imaging, but these 
likely represent a low percentage of patients. 
Women who are anxious about a false positive 
should have 3D-tomosynthesis, because this 
technology reduces recalls by 15% to 30% 
while increasing detection of invasive cancers 
by 30% to 40%.
3-6
 
Screening intervals. Annual screening results 
in the largest reduction in breast cancer 
mortality. The tradeoff is a greater risk of false-
positive mammography and false-positive 
biopsy. Again, the risk of anxiety related to a 
false-positive mammogram is low for the vast 
majority of women compared with the benefit of 
reduction in breast cancer mortality. The risk of 
false-positive biopsy over a decade is 7% for 
annual and 4.8% for biannual screening.
7
 The 
absolute increase in false-positive biopsies by 
using annual compared to biannual 
mammography translates to two false-positive 
biopsies being performed each year per 
1,000 women screened. At the per-woman level, 
this risk is minimal. In addition, more than 95% 
of diagnostic breast biopsies are minimally 
invasive image-guided needle biopsies. 
 
Can women at average risk safely reduce 
screening intervals at age 55? The big problem 
with moving to a risk-based approach to 
screening is that risk identification strategies are 
terribly inaccurate. Current breast cancer risk 
models have high calibration (an indicator of 
function at the population level) but low 
discrimination (an indicator of performance at 
the individual level), even for models including 
extensive risk factors such as the Tyrer-Cuzick 
model.
8
 
 
Current models do not account for dense breast 
tissue, which increases the risk of breast cancer 
by 2 to 4 times and increases the risk of a false-
negative mammogram.
9
 Women with dense 
breasts should continue to undergo yearly 
mammography and consider additional 
screening with ultrasound. 
 
Women wanting to maximize the benefits of 
screening should start at age 40 and obtain 
annual mammograms for as long as they remain 
in good health and have a life expectancy of 
10 years or longer. Women with dense breast 
tissue should continue annual screening and at 
least consider ancillary screening. Women who 
are anxious about false-positive results should 
strongly consider having 3D-tomosynthesis 
mammography. Regular screening not only 
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reduces breast cancer mortality but also reduces 
the treatment of disease when detected. 
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Review of menopause symptom 
treatment stresses staying current 
on data and individualizing care 
 
Kaunitz AM, Manson JE. Management of menopausal 
symptoms. Obstet Gynecol. 2015;126(4):859-876. 
 
Summary. A comprehensive review article 
reports on updates in the treatment of 
menopause symptoms, including vasomotor 
symptoms (VMS) and the genitourinary 
syndrome of menopause. The latest information 
on hormone therapy (HT), including the 
different HT options (oral vs transdermal) and 
varying doses, is presented and explained. 
 
Nonhormonal treatment options, including 
behavioral treatments for hot flashes, selective 
serotonin reuptake inhibitors, serotonin-
norepinephrine reuptake inhibitors, paroxetine, 
escitalopram, citalopram, venlafaxine, desven-
lafaxine, gabapentin, and pregabalin, are 
explained, along with their benefits and risks. 
 
Other information included in this review article 
is an overview of menopause, including 
symptoms, demographics, natural history, and 
the risk factors for different symptoms. 
 
Special patient populations that may be 
particularly challenging are also addressed. 
These include women with early menopause, 
women with a history of or increased risk for 
breast cancer or who carry the BRCA gene, 
women with a history of venous thrombo-
embolism or endometriosis, and women who 
have persistent menopause symptoms of a very 
long duration or who may request an extended 
duration of HT treatment. 
 
Rather than stopping systemic HT at age 65, the 
authors suggest that length of treatment should 
be individualized on the basis of a woman’s risk 
profile and preferences. They also suggest the 
use of benefit-risk profile tools for hormone and 
nonhormone options to help women make sound 
decisions on treatment. 
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his excellent, updated review article is 
worthy of attention by any practitioner T 
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caring for perimenopausal, postmenopausal, and 
menopausal women. It capsulizes an enormous 
literature and fairly presents a major evolution 
of changes in our approach to therapy for 
menopause symptoms since the publication of 
the Women’s Health Initiative (WHI) study. 
 
That stated, there are some additional points that 
should be included, understanding that this is a 
review article and not a book. For one, although 
we all agree that the pathophysiology of VMS 
remains poorly characterized, Freedman has not 
only shown that the set point of the 
thermoregulatory system is lowered as stated, 
but he has helped us to rule out the decreased 
endorphins and pulsatile luteinizing hormone 
secretion as causative factors.
1
 
 
In addition, when only moderate and severe 
flashes are considered worthy of treatment, an 
attempt should be made to define them, even 
though it is certainly subjective. The US Food 
and Drug Administration gave these definitions 
as guidelines to industry that are widely used in 
studies: Mild feeling of heat with no sweating; 
moderate feeling of heat with sweating but able 
to continue activity; severe feeling of heat with 
sweating causing cessation of activity.
2
 
 
It is important to consider the associated 
morbidity that accompanies symptoms.
3
 
Whiteley and associates observed that in 
postmenopausal women, a greater severity of 
VMS is significantly associated with lower 
levels of health status and work productivity and 
greater healthcare resource use.
4
 
 
Thurston and colleagues’ extensive Study of 
Women’s Health Across the Nation showed that 
hot flashes were associated with a higher 
incidence of insulin resistance, and to a lesser 
extent, higher glucose.
5
 
 
And in a subgroup analysis from the Women’s 
Health Initiative trials of HT, higher risks of 
cardiovascular disease were shown in women 
with a higher burden of menopausal symptoms.
6
 
Those experiencing symptomatic menopause 
had significantly increased risk for coronary 
heart disease (hazard ratio [HR], 5.08; 95% 
confidence interval [CI], 2.08-12.40) compared 
with their counterparts with a lower burden of 
menopausal symptoms. Similarly, the risk of 
stroke was significantly elevated (HR, 3.94; 
95% CI, 1.09-1.14). This analysis has supported 
the hypothesis that menopause symptoms 
convey cardiovascular risk. 
 
It is also apparent from Greene’s positron 
emission tomography studies in 2007 that there 
is significant decrease in cerebral blood flow 
during a hot flash.
7
 This explains a woman’s 
inability to continue her tasks during a hot flash. 
 
The issue of estrogen alone versus estrogen-
progestin in the benefit-risk ratio is certainly 
covered but should be stressed. The off-label 
use of progestin-releasing intrauterine devices is 
noted, but the availability of a lower-dose, 
smaller device should be mentioned as more 
appropriate for menopausal women.
8
 
 
The conjugated estrogen (CEE)-bazedoxifene 
(BZA) combination may indeed be one answer 
as we receive more information. Clarkson’s 
monkey study is hopeful in showing that CEE 
inhibits the progression and complications of 
both coronary and iliac artery atherosclerosis, 
and BZA has no adverse effects on 
atherosclerosis in postmenopausal monkeys.
9
 
 
Because decrease in sexual desire is often a 
menopausal symptom, testosterone issues need 
to be addressed, although no testosterone 
medication has been approved by FDA. In a 
6-month placebo-controlled study, followed by 
a 4-year follow-up of treated patients, a 300-µg 
patch daily (considered a low physiologic dose) 
showed statistically significant improvement in 
all aspects of sexual function, including 
successful and satisfying sexual desire.
10
 
 
Kaunitz and Manson should be applauded for 
their exhaustive review and for including many 
controversies with their opinions. Of particular 
note is the reference to the package insert for 
low-dose vaginal estrogens, which becomes 
problematic in clinical use, and the outdated 
6 
recommendation of the American Geriatric 
Society to not treat women aged older than 
65 years with estrogen. This has led to denial of 
medication by insurance companies. 
 
The authors have given deserved credit to The 
North American Menopause Society and to the 
American Congress of Obstetricians and 
Gynecologists for fighting for individualizing 
hormone medications and treating symptoms 
regardless of age. 
 
The authors should be commended as well for 
helping to bring clinicians up-to-date on the 
enormous significant data that address the 
benefit-risk profile of HT and point out that 
although there are contraindications, absolute 
risks are small. Their conclusion that remaining 
abreast of new information is essential in aiding 
women regarding management of menopausal 
symptoms should be a guiding principle.  
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Merits, demerits of proposed 
redefined diagnostic criteria 
for osteoporosis 
 
Kanis JA, McCloskey EV, Harvey NC, Johansson H, 
Leslie WD. Intervention thresholds and the diagnosis of 
osteoporosis. J Bone Miner Res. 2015;30(10):1747-1753. 
 
Summary. A recent position paper of the 
National Bone Health Alliance (NBHA) has 
recommended that diagnostic criteria for osteo-
porosis be redefined to more closely reflect 
National Osteoporosis Foundation (NOF) 
treatment thresholds. Current World Health 
Organization (WHO) diagnostic criterion for 
osteoporosis is based on the measurement of 
bone mineral density (BMD). Osteoporosis is 
described as a BMD at the femoral neck of 
2.5 standard deviations (SD) or more below the 
young female adult mean (T-score ≤–2.5 SD). 
 
The NBHA proposes to broaden the definition 
of osteoporosis that adds additional criteria to 
include patients with fragility fractures and at 
“high risk for fracture.” Using clinical, global, 
and economic reasoning, Kanis and colleagues 
provide arguments for and against this definition 
of osteoporosis. 
 
Ultimately, Kanis and colleagues find the 
redefined diagnostic criteria “cumbersome” and 
likely to deter the management of osteoporosis 
in routine clinical practice. 
 
They suggest an eventual balance for the 
diagnostic criteria for osteoporosis between 
sensitivity and clinical justification, as done 
recently for cardiovascular disease. They argue 
that the diagnostic criteria should still be based 
on BMD and question the need for diagnostic 
7 
criteria when the field, as other fields, is moving 
toward risk-based assessment and intervention. 
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onfusion exists between the definition of 
and the diagnostic criteria for multifactorial 
clinical disorders such as osteoporosis, 
hypertension, and hyperlipidemia. 
 
Each of these disorders has several pathogenetic 
mechanisms, and each becomes clinically 
apparent only when complications such as 
fracture, stroke, or heart attack occur. 
 
At the beginning of my career, osteoporosis was 
the diagnosis when a patient, typically an older 
postmenopausal woman, presented with a 
fracture of her spine, hip, or shoulder. 
Osteoporosis was defined as a disorder of low 
bone mass, specifically, “a medical condition in 
which the bones become brittle and fragile from 
loss of tissue, typically as a result of hormonal 
changes, or deficiency of calcium or 
vitamin D.”1 
 
Osteoporosis was one of the osteopenias (the 
original meaning of that word), but unlike 
osteomalacia and other forms of osteopenia, the 
quality of bone in osteoporosis appeared normal 
by light microscopy. 
 
However, based on histomorphometric studies 
by Parfitt and others, we came to appreciate that 
disrupted microarchitecture, in addition to low 
bone mass, was an important component of 
osteoporosis.
2
 
 
The beautiful scanning electron microscopic 
images of trabecular bone by David Dempster
3
 
and of cortical porosity by Dr. Zabeze
4
 
augmented this understanding. 
 
As the complex pathogenesis of skeletal 
fragility unfolded and our insight into the 
multiple determinants of bone strength 
improved, the definition of osteoporosis 
evolved, leading to the inclusion of 
“microarchitectural deterioration” as a requisite 
component.
5
 
 
Although this is an accurate description of the 
disease, the influence of structure is difficult to 
incorporate into a diagnostic criterion because, 
until recently, it could not be assessed in 
individual patients, and even today, we can only 
do that with expensive research techniques.  
 
The confusion between the definition and 
diagnosis of osteoporosis is amplified for two 
historical reasons: First, the term osteoporosis 
was originally (as is still) used as the diagnosis 
in patients who presented with a fragility 
fracture of the hip or spine. 
 
However, in 1994, on the basis of epidemiologic 
but not clinical considerations, the World Health 
Organization (WHO) defined osteoporosis in 
postmenopausal women as a bone mineral 
density (BMD) T-score value of –2.5 or less.6 
By this definition, osteoporosis was redefined; 
no longer a clinical event, but as an important 
(but not the only) risk factor for fracture. 
 
Unlike the relationship between high blood 
pressure (risk factor) and stroke (a clinical 
event), the same word was used to define both 
the risk factor and the clinical consequence. We 
are then left with the confusing situation of 
making the diagnosis of osteoporosis on both 
clinical criteria (patients who present with spine 
or hip fracture), regardless of T-score, and in 
those who meet the BMD diagnostic criteria. 
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Second, the term low bone mass (or 
unfortunately, osteopenia) was defined by the 
WHO as a T-score value between –1 and –2.5, 
overlapping the normal range of BMD in 
healthy young adults, which is –2 up to +2. 
Thus, the true definition of low bone mass is a 
T-score value of less than –2.  
 
The article by Kanis and colleagues comes in 
response to a paper by the National Bone Health 
Alliance (NBHA), an American organization, 
that proposed broadening the definition of 
osteoporosis to include patients with certain 
fractures and patients at high risk for fracture.
7 
That suggestion was based on the reluctance of 
American insurance companies to cover 
osteoporosis medications in patients who are at 
high risk for fracture but who do not meet the 
WHO BMD diagnostic criteria. Wedding the 
diagnostic and treatment criteria would perhaps 
solve this uniquely American problem.  
 
Kanis reviews the history of and rationale for 
the diagnostic criteria for osteoporosis on the 
basis of BMD and clearly makes the distinction 
between how we define and diagnose the 
condition and how we decide who should 
receive osteoporosis treatment. The necessary 
disparity between diagnostic and treatment 
criteria is shared with other clinical disorders. 
 
Updated treatment guidelines for using statin 
therapy to reduce cardiovascular risk have 
moved away from specific low-density 
lipoprotein values as a treatment threshold 
toward identifying and treating patients at high 
risk, just as we have done in the osteoporosis 
field.
8
 Not surprisingly, those new guidelines 
engendered a spirited debate.
9,10
 
 
Kanis also makes the important point that the 
WHO operational definition of osteoporosis has 
been well received by and functions very well in 
the rest of the world, in which the awkward 
relationships between payers and patients or 
physicians found in our country do not exist. 
 
The Kanis paper is an important reference 
outlining the relationships between definitions, 
diagnostic criteria, and treatment thresholds. It 
should be read (and re-read) by all of us who 
make decisions about when to treat 
osteoporosis, hypertension, or hyperlipidemia 
and especially for those who take part in the 
challenging task of developing diagnostic 
criteria and treatment guidelines for complex 
medical problems with multiple distinct and 
independent determinants. 
 
Were we to have a fresh start in the osteoporosis 
field, we would do a much better job of being 
specific and precise in our terminology. We 
would define low bone mass correctly as a 
T-score of less than –2, emphasizing the 
importance of this risk factor for fracture, just as 
elevated blood pressure and high lipid levels are 
used in other fields. 
 
The utility of combining low bone mass with 
other risk factors such as advanced age and 
history of prior fracture to make assessments of 
fracture risk in individual patients would be 
recognized, as we have done with the FRAX 
tool. We would clearly define our therapeutic 
goal—to prevent fractures, or as we do in 
Portland, to make it even clearer to patients, to 
prevent “bone attacks.” 
 
The term osteoporosis would either revert to its 
early meaning as a specific pathologic condition 
and would not be used to define a risk factor for 
fracture or a patient with a fracture or become a 
more general term, analogous to cerebrovascular 
disease. 
 
More practically, the problem that the NBHA 
attempted to address could be more easily 
solved by a simple change in the labeling of 
osteoporosis mediations by FDA. By approving 
drugs “for the treatment of patients at high risk 
of fracture” rather than for treating osteoporosis, 
a major component of the reimbursement 
difficulties would evaporate. 
 
9 
There is precedent in the lipid field in which 
statins are indicated to “reduce the risk of MI, 
stroke . . . in patients with CHD or without 
CHD, but with multiple risk factors.”11 Such a 
proposal was made at a recent FDA workshop 
on osteoporosis therapy. We should advocate 
for such a strategy, rather than confusing 
ourselves with yet another definition of 
osteoporosis. 
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In Other News 
NAMS presents summaries of other recently 
published articles for your review 
Menopause status affects onset of 
asthma and other respiratory symptoms 
Triebner K, Johannessen A, Puggini L, et al. Menopause 
as a predictor of new-onset asthma: a longitudinal 
Northern European population study [published online 
ahead of print October 1, 2015]. J Allergy Clin Immunol. 
 
Because of limited and conflicting evidence on 
the effect of menopause on asthma, researchers 
in this longitudinal population-based study 
sought to learn whether the incidence of asthma 
and respiratory symptoms differ by menopause 
status. 
 
The Respiratory Health in Northern Europe 
study provided questionnaire data pertaining to 
respiratory and reproductive health at baseline 
and follow-up. 
 
The study cohort included women aged 45 to 65 
years at follow-up, without asthma at baseline, 
and not using hormone therapy (n=2,322). 
 
Menopause status was defined as 
nonmenopausal, transitional, early post-
menopausal, and late postmenopausal. 
 
Associations with asthma (defined by the use of 
asthma medication, having asthma attacks, or 
both) and respiratory symptoms scores were 
analyzed by using logistic (asthma) and negative 
binomial (respiratory symptoms) regressions, 
adjusting for age, body mass index, physical 
activity, smoking, education, and study center. 
 
The odds of new-onset asthma were increased in 
women who were transitional (odds ratio [OR], 
2.40; 95% confidence interval [CI], 1.09-5.30), 
early postmenopausal (OR, 2.11; 95% CI, 1.06-
4.20), and late postmenopausal (OR, 3.44; 95% 
CI, 1.31-9.05) at follow-up compared with 
nonmenopausal women. The risk of respiratory 
symptoms increased in early postmenopausal 
(coefficient, 0.40; 95% CI, 0.06-0.75) and late 
10 
postmenopausal (coefficient, 0.69; 95% CI, 
0.15-1.23) women. 
 
These findings were consistent regardless of 
smoking status and across all study centers. 
 
Menopause Editor’s picks 
for November 2015 
 
Associations between body mass index and sexual 
functioning in midlife women: the Study of Women’s 
Health Across the Nation 
Lisa M. Nackers, PhD, MPH; Bradley M. Appelhans, 
PhD; Eisuke Segawa, PhD; Imke Janssen, PhD; 
Shelia A. Dugan, MD; and Howard M. Kravitz, DO, 
MPH 
♦ 
Cluster analysis of midlife women’s sleep-related 
symptoms: racial/ethnic differences 
Eun-Ok Im, PhD, MPH, RN, CNS, FAAN; Ko Young, 
PhD; Eunice Chee, BS(c); and Wonshik Chee, PhD 
♦ 
Confirmatory factor analysis of the Pittsburgh Sleep 
Quality Index in women with hot flashes 
Julie L. Otte, PhD, RN; Kevin L. Rand, PhD; 
Carol A. Landis, PhD, RN, FAAN; Misti L. Paudel, PhD; 
Katherine M. Newton, PhD; Nancy Woods, PhD, RN, 
FAAN; and Janet S. Carpenter, PhD, RN, FAAN 
♦ 
One-year treatment persistence with local estrogen 
therapy in postmenopausal women diagnosed as 
having vaginal atrophy 
David Portman, MD; Lee Shulman, MD; Jason Yeaw, 
MPH; Sha Zeng, MSc; Chioma Uzoigwe, MPH; 
Ricardo Maamari, MD, NCMP; and Neeraj N. Iyer, PhD  
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